ReviewInternational journal of molecular sciences2024
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies.Medical oncology (Northwood, London, England) · 2026Review
- CTSC Confers Radioresistance in Hepatocellular Carcinoma by Regulating Myeloid-Derived Suppressor Cells.Journal of cellular and molecular medicine · 2026Article
- Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals.American journal of translational research · 2026Article
- Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside.Frontiers in immunology · 2026Review
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- Transposable Element Dysregulation in Hepatocellular Carcinoma: Epigenetic Mechanisms, Immune Remodeling, and Translational Opportunities.Journal of hepatocellular carcinoma · 2026Review
- Artificial intelligence-based prognostic modeling of immunoradiotherapy in Barcelona clinic liver cancer stage C hepatocellular carcinoma: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma.Scientific reports · 2025Article
- Cytokine release syndrome complicated with sepsis induced by tislelizumab in a patient with advanced hepatocellular carcinoma: A case report.Human vaccines & immunotherapeutics · 2025Article
- MCRS1 is associated with immunosuppressive microenvironments in pan-cancer and promotes hepatocellular carcinoma malignant phenotypes.Translational cancer research · 2025Article
- Relative treatment effects of first-line chemotherapy and immunotherapy for hepatocellular carcinoma: A systematic review and meta-analysis.Cancer pathogenesis and therapy · 2025Review
- Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.Journal of liver transplantation · 2025Article
- Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.Discover oncology · 2025Review
- Evaluation of the efficacy of laparoscopic hepatolobectomy for primary liver cancer with early combined enteral and parenteral nutritional support.Discover oncology · 2025Article
- Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study.Cancer immunology, immunotherapy : CII · 2025Article
- Unraveling the oncogenic role of LINC00504 and its interaction with miR-545-3p and ARIHI in hepatocellular carcinoma: novel insights for molecular therapy.Discover oncology · 2025Article
- Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response.Journal of clinical medicine · 2025Article
- m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.Frontiers in immunology · 2025Review
- Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study.Frontiers in oncology · 2025Article
- Single-cell and spatial transcriptomics reveal correlation between RNA methylation-related miRNA risk model and immune infiltration in hepatocellular carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs), such as durvalumab, tremelimumab, and atezolizumab, have emerged as a significant therapeutic option for the treatment of hepatocellular carcinoma (HCC). In fact, the efficacy of ICIs as single agents or as part of combination therapies has been demonstrated in practice-changing phase III clinical trials. However, ICIs confront several difficulties, including the lack of predictive biomarkers, primary and secondary drug resistance, and treatment-related side effects. Herein, we provide an overview of current issues and future challenges in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.